Exploration of Cytokines That Impact the Therapeutic Efficacy of Mesenchymal Stem Cells in Alzheimer’s Disease
Bioengineering · 12.06.2025 · 12 (6) · 646
DOI: 10.3390/bioengineering12060646 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioengineering, online erschienen am 12.06.2025. Verfasst von Herui Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cell Biology and Regenerative Medicine Department, Yi-Chuang Institute of Bio-Industry, Beijing 100176, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Beijing Municipal Science and Technology Project.
Themen: Demenz
Abstract (Originalsprache)
Current therapies for Alzheimer’s disease (AD) includes acetylcholinesterase inhibitors, NMDA receptor antagonists, and amyloid beta (Aβ)/Tau-targeting drugs. While these drugs improve cognitive decline and target the pathological mechanisms, their outcomes still are still in debate. Mesenchymal stem cells (MSCs) offer a regenerative approach by modulating neuroinflammation and promoting neuroprotection. Although the paracrine of MSCs is efficient in various AD preclinical studies and the exosomes of MSCs have entered clinical trials, the key cytokines driving the efficacy remain unclear. Here, we evaluated human umbilical cord-derived MSCs (hUC-MSCs) and employed gene-silenced MSCs (siHGF-MSCs, siTNFR1-MSCs, siBDNF-MSCs) in APP/PS1 AD mice to investigate specific mechanisms. hUC-MSCs significantly reduced Aβ/Tau pathology and neuroinflammation, with cytokine-specific contributions: silencing HGF predominantly reduced Aβ/Tau clearance, although silencing TNFR1 or BDNF showed modest effects; silencing TNFR1 or BDNF more prominently weakened anti-neuroinflammation, while silencing HGF exerted a weaker influence. All three cytokines partially contributed to oxidative stress reduction and cognitive improvements. Our study highlights MSC-driven AD alleviation as a multifactorial strategy and reveals specific cytokines alleviating different aspects of AD pathology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Stem Cell Biology and Regenerative Medicine Department, Yi-Chuang Institute of Bio-Industry, Beijing 100176, China.
- Department of Anesthesiology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
ORCID-Profile: Herui Wang, Guangyang Liu
Förderung
- National Key Research and Development Program of China
- Beijing Municipal Science and Technology Project
Zitieren
APA
Wang, H., Zhong, C., Mi, Y., Li, G., Zhang, C., Chen, Y., Li, X., Liu, Y., & Liu, G. (2025). Exploration of Cytokines That Impact the Therapeutic Efficacy of Mesenchymal Stem Cells in Alzheimer’s Disease. Bioengineering, 12(6), 646. https://doi.org/10.3390/bioengineering12060646
Vancouver
Wang H, Zhong C, Mi Y, Li G, Zhang C, Chen Y, et al. Exploration of Cytokines That Impact the Therapeutic Efficacy of Mesenchymal Stem Cells in Alzheimer’s Disease. Bioengineering. 2025;12(6):646. doi:10.3390/bioengineering12060646
BibTeX
@article{Wang2025,
author = {Wang, Herui and Zhong, Chonglin and Mi, Yi and Li, Guo and Zhang, Chenliang and Chen, Yaoyao and Li, Xin and Liu, Yongjun and Liu, Guangyang},
title = {Exploration of Cytokines That Impact the Therapeutic Efficacy of Mesenchymal Stem Cells in Alzheimer’s Disease},
journal = {Bioengineering},
year = {2025},
volume = {12},
number = {6},
pages = {646},
doi = {10.3390/bioengineering12060646}
}
EUVIMED